Please assess the completion status of the following clinical trial:

Trial Title: Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of idiopathic pulmonary fibrosis that fulfills American Thoracic Society Consensus Criteria.~* Unexplained worsening or development of dyspnea or hypoxemia within 30 days leading to the current hospitalization.~* Radiographic imaging showing ground-glass abnormality and/or consolidation superimposed on a background of reticular or honeycomb pattern consistent with usual interstitial pneumonia.~* Intent on the part of the treating physician to use high dose steroid therapy as a therapeutic effort to treat a diagnosis of acute IPF exacerbation.~Exclusion Criteria:~* Diagnosis of documented infection based upon clinical evaluation and microbial testing.~* Diagnosis of thromboembolic disease by clinical assessment.~* Diagnosis of an additional etiology for Acute Lung Injury/Acute Respiratory Distress Syndrome based upon clinical assessment to include sepsis, aspiration, trauma, inhalational injury, acute pancreatitis, drug toxicity, blood product transfusion reaction, or stem cell transplantation.~* Diagnosis of congestive heart failure that accounts for the hypoxemia.~* Presence of active hepatitis B infection.~* Coagulopathy defined as an International Normalized Ratio \> 1.8, Partial Thromboplastin Time \> 2 x control, and platelet count \< 50,000.~* Hyperosmolar state or diabetic ketoacidosis to suggest uncontrolled diabetes mellitus or uncontrolled hypertension (systolic BP \> 160 mm Hg and diastolic BP \> 100 mm Hg) which would contraindicated the use of corticosteroids.~* Hemodynamic instability defined as a vasopressor requirement which would contraindicate the use of plasmapheresis.~* History of reaction to blood products, murine-derived products, or prior exposures to human-murine chimeric antibodies,~* History of malignancy.~* Inability or unwillingness to accept a blood transfusion.~* Inability or unwillingness to complete post- treatment surveillance for 60 days.~* Diagnosis of major comorbidities expected to interfere with subjects study participation for 60 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Combined PEX, Rituximab and Steroids (Type: EXPERIMENTAL): Standard Steroid Treatment: One gm of methylprednisolone I.V., on day 0, followed by 40 mg/day I.V. on days 1-4, and days 6-12 (or the P.O. prednisone equivalent). Methylprednisolone 100 mg I.V. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone I.V. (or P.O. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the principle investigator.~Plasma exchange (PEX) will consist of 1.5x estimated plasma volume exchanges for 3 successive days (0, 1,2) and then, after a one day interval to enable equilibration of autoantibodies sequestered in tissues, two more daily treatments on days 4 and 5.~Rituximab: One gm I.V. will be administered on day 5 (after completion of the last PEX) and day 13.

Based on this trial design, predict the completion outcome and termination type (if applicable).